Article Text

other Versions

PDF
Original article
p21 promotes sustained liver regeneration and hepatocarcinogenesis in chronic cholestatic liver injury
  1. Silke Marhenke1,
  2. Laura Elisa Buitrago-Molina1,
  3. Jessica Endig1,
  4. Johanna Orlik1,
  5. Nora Schweitzer1,
  6. Stephanie Klett1,
  7. Thomas Longerich2,
  8. Robert Geffers3,
  9. Aránzazu Sánchez Muñoz4,
  10. Craig Dorrell5,
  11. Sarah-Fee Katz6,
  12. André Lechel6,
  13. Honglei Weng7,
  14. Till Krech8,
  15. Ulrich Lehmann8,
  16. Steven Dooley7,
  17. Karl Lenhard Rudolph9,
  18. Michael P Manns1,
  19. Arndt Vogel1
  1. 1Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
  2. 2Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
  3. 3Genome Analytics Group, Helmholtz Centre for Infection Research, Braunschweig, Germany
  4. 4Departamento de Bioquímica y Biología Molecular II, Universidad Complutense de Madrid, Madrid, Spain
  5. 5Department of Genetics, Oregon Stem Cell Center, Oregon Health & Science University, Portland, USA
  6. 6Department of Internal Medicine 1, Ulm University Hospital, Ulm, Germany
  7. 7Department of Medicine II, Molecular Hepatology—Alcohol Associated Diseases, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
  8. 8Department of Pathology, Medical School Hannover, Hannover, Germany
  9. 9Leibniz Institute for Age Research, Fritz Lipmann Institute, Jena, Germany
  1. Correspondence to Professor Arndt Vogel, Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover 30625, Germany; vogel.arndt{at}mh-hannover.de

Abstract

Background and aims The cyclin-dependent kinase inhibitor p21 has been implicated as a tumour suppressor. Moreover, recent genetic studies suggest that p21 might be a potential therapeutic target to improve regeneration in chronic diseases. The aim of this study was to delineate the role of p21 in chronic liver injury and to specify its role in hepatocarcinogenesis in a mouse model of chronic cholestatic liver injury.

Methods The degree of liver injury, regeneration and tumour formation was assessed in Mdr2−/− mice and compared with Mdr2/ p21−/− mice. Moreover, the role of p21 was evaluated in hepatoma cells in vitro and in human hepatocellular carcinoma (HCC).

Results Mdr2−/− mice developed HCCs as a consequence of chronic inflammatory liver injury. In contrast, tumour development was profoundly delayed in Mdr2/ p21−/− mice. Delayed tumour development was accompanied by markedly impaired liver regeneration in Mdr2/ p21−/− mice. Moreover, the regenerative capacity of the Mdr2/ p21−/− livers in response to partial hepatectomy declined with age in these mice. Hepatocyte transplantation experiments revealed that impaired liver regeneration was due to intrinsic factors within the cells and changes in the Mdr2/ p21−/− microenvironment. In human HCCs, a subset of tumours expressed p21, which was associated with a significant shorter patient survival.

Conclusions We provide experimental evidence that p21 is required for sustained liver regeneration and tumour development in chronic liver injury indicating that p21 needs to be tightly regulated in order to balance liver regeneration and cancer risk. Moreover, we identify p21 as a negative prognostic marker in human HCC.

  • LIVER
  • CELL CYCLE CONTROL
  • CANCER
  • HEPATOCELLULAR CARCINOMA

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles